secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001104659-25-061375
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025
--------------------------------------------------------------------------------

- 16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.
- 41% (7/17) confirmed CNS complete response; 53% CNS ORR in CNS-evaluable patients by BICR.
- Safety consistent with prior data: no Grade 4/5 TRAEs, no discontinuations due to TRAEs; most common TRAEs diarrhea, elevated liver enzymes, rash.
- Firmonertinib 240 mg selected for pivotal Phase 3; ALPACCA trial enrollment expected to start H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/0001104659-25-061375-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925061375/tm2518615d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061375

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer